A French startup that wants a robot rather than a dentist's hand to shave down teeth for veneers has raised EUR 15 million to get the machine into clinics — in every market except its own.

Lupin Dental closed a Series A round of EUR 15 million, reported by Dental Asia as roughly USD 17.5 million. Fynveur led with EUR 10 million. Existing shareholders and new private investors took the rest, alongside a loan from state bank Bpifrance. Invus, which advises Fynveur, is joining the board. No valuation was disclosed and no prior funding was detailed. Two notes on the deal-feed listing: press coverage places the company's headquarters in Montpellier, not Marseille, though TechFundingNews reports a Marseille office; and the dollar figure moves with the conversion used, from about USD 16.4 million to USD 17.5 million.

What the company does

Lupin Dental was founded in 2019 by two cosmetic dentistry practitioners, Dr. Galip Gurel and Dr. Stefen Koubi. Its product, the Lupin Robotic System, is a supervised automated platform for minimally invasive tooth preparation ahead of aesthetic veneers. Software handles the smile design and treatment plan; a robotic workstation then executes that plan on the tooth while the dentist supervises.

The pitch rests on a simple asymmetry: enamel removed cannot be put back. Veneer preparation is a manual, irreversible procedure where a fraction of a millimeter separates a good result from an expensive one, which is the argument for handing the cutting to a machine working from a plan. In Great Britain the system is marketed as the Dolphin Robotic Dental System, according to TechFundingNews, which puts headcount at around 50.

The numbers behind the round

Two thirds of the round came from one investor. Fynveur's EUR 10 million dwarfs the combined contribution of existing shareholders and the new private investors, and part of the remainder is not equity at all but a Bpifrance loan — so the Series A label covers a mixed structure rather than a single priced round. Neither the company nor Surgical Robotics Technology disclosed a post-money valuation, and no earlier round has been made public, which makes the seven years between founding and this raise hard to read.

The money is earmarked for partnerships with academic and medical institutions, individual dentists and Dental Service Organizations — the last of which matters most commercially, since chains rather than single practices are the buyers who can absorb capital equipment.

Why the timing matters

The round follows UKCA certification in June 2026, which cleared the system for sale in Great Britain, adding to an existing regulatory clearance in India. It is not approved for clinical use in the United States or the European Union.

That is the uncomfortable fact underneath the raise. A French company, backed in part by a French state bank, cannot sell its robot in France. Its addressable market today is Great Britain and India, and the capital is effectively buying time to work through American and European regulators while generating revenue in the two geographies it can reach. Aesthetic dentistry is cash-pay and price-insensitive at the top end, which makes it an unusually forgiving place to prove a surgical robot — but it also means the clinical evidence base that US and EU approval will demand has to be built in markets where nobody is requiring it yet.

Source

EU-Startups — "Montpellier-based dental robotics startup Lupin Dental closes EUR 15 million Series A round"